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A high-throughput polymer microarray approach
for identifying deﬁned substrates for mesenchymal
stem cells†
Cairnan R. E. Duﬀy,‡a Rong Zhang,‡b Siew-Eng How,c Annamaria Lilienkampf,d
Guilhem Tourniaire,d Wei Hu,b Christopher C. West,e Paul de Sousa*a and
Mark Bradley*d
Mesenchymal stem cells (MSCs) hold great promise in regenerative medicine due to their wide multiline-
age potential as well as their ability to suppress/modulate the immune response. Maintaining these cells
in vitro and expanding them on a clinically relevant scale remains a challenge that needs to be addressed
to realise their full potential. Current culture methods for MSCs typically rely on animal sourced substrates
and often result in a heterogeneous population of cells with varying degrees of diﬀerentiation capacity.
Here, a high-throughput platform was used to identify synthetic substrates for MSC culture that not only
facilitated growth but also maintained the MSC phenotype. Two polymers, PU157 (synthesised from
poly(butyleneglycol) and 4,4’-methylenediphenyldiisocyanate with 3-(dimethylamino)-1,2-propanediol as a
chain extender) and PA338 (N-methylaniline modiﬁed poly(methylmethacrylate-co-glycidylmethacrylate))
were able to maintain the growth and phenotype of human embryonic derived mesenchymal progenitors
(hES-MPs) and adipose derived MSCs (ADMSCs) for ﬁve and ten passages, respectively. Cell phenotype
and multipotency were conﬁrmed by ﬂow cytometry analysis of ten MSC markers and diﬀerentiation ana-
lysis. These new polymer substrates provide a chemically deﬁned synthetic surface for eﬃcient, long-
term MSC culture.
Introduction
Mesenchymal stem cells (MSCs) were first isolated from a
bone marrow aspirate by Friedenstein as a ‘rare population’ of
fibroblastic cells termed ‘colony forming units’.1 Subsequently,
MSCs have been isolated from various sources including umbi-
lical cord blood,2 Wharton’s jelly,3 adipose tissue,4 and other
vascularised tissues. This wide variety of sources arises from
their in vivo niche adjacent to the vasculature.5 MSCs exhibit
multilineage potential and can diﬀerentiate into osteogenic,
adipogenic and chondrogenic lineages6 as well as to other cell
types such as smooth muscle7 and neurons.8 The remarkable
multilineage diﬀerentiation capacity and access has made
MSCs the focus of numerous applications in tissue engineer-
ing.9 Furthermore, MSCs have been shown to possess the
ability to modulate the immune system and have been co-
transplanted as a treatment for graft versus host disease.10 A
number of studies are currently underway where the immune
modulatory property of MSCs is being applied in the treatment
of autoimmune diseases such as type 1 diabetes,11 multiple
sclerosis,12 and arthritis.13
Given the clinical importance of MSCs, their culture is
crucial for any downstream application. MSCs grown on tissue
culture plastic have been shown to lose both osteogenic and
adipogenic potential when compared to gelatin.14,15 On the
other hand, the use of animal derived substrates such as
gelatin, collagen or fibronectin is problematic due to the pres-
ence of a multitude of undefined factors, batch variation, and
the potential for pathogen transfer. In order to capitalise on
the full clinical potential of MSCs, there is undoubtedly a
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pressing need for defined synthetic substrates for long-term
culture. Since MSC populations contain cells of varying
degrees of multipotency,16 the ideal substrate would also only
enrich the most multipotent cell type.
Polymer microarrays allow the high-throughput interro-
gation of defined surfaces for various biomedical appli-
cations.17,18 For example, polymer microarrays have enabled
the identification of polymers that capture protozoan patho-
gens,19 resist bacterial adhesion,20 or activate platelets.21 In
stem cell research, polymer microarrays have been used to
identify polymers that can support human embryonic stem
cells (hESCs) in undefined22 and defined media.23 Thermo-
responsive hydrogels have also been identified that can main-
tain MSCs in undefined, and hESCs in defined, media in the
absence of enzymatic or chemical passaging.24,25 Besides sub-
strates that promote adhesion and growth, polymer micro-
arrays enable the screening for substrates that can maintain or
enhance the MSC phenotype, i.e., cells can be evaluated for
multiple MSC markers in a high-throughput manner.
In this study, the high-throughput screening strategy out-
lined in Fig. 1 was used to identify polymers as MCS sub-
strates. This approach yielded polymers that showed good
cellular adhesion and proliferation for both human embryonic
derived mesenchymal progenitors (hES-MPs) and adipose
derived mesenchymal stem cells (ADMSCs), while maintaining
the expression of several MSC markers, as well as their diﬀer-
entiation potential in long-term culture. In the screening
process, hES-MPs were utilised as a stable and readily available
surrogate for adult derived MSCs.
Materials and methods
Materials
Reagents for cell culture were purchased from Invitrogen
unless otherwise stated. Other chemicals were from Sigma
Aldrich.
Cell culture
All cells were maintained in a humidified incubator at 37 °C
with 5% CO2. ADMSCs were derived from the stromal vascular
fraction of lipoaspirate4 and grown in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% FCS, bFGF
(4 ng mL−1), L-glutamine (100 units mL−1) and pen/strep
(100 units mL−1) with media changes every 2–3 days. Ethical
approval for the collection of adipose tissue and subsequent
research was granted by the South East Scotland Research
Ethics Committee (Ref 10/S1103/45 h). hES-MPs
(hES-MP™002.5, Cellectis bioresearch) were cultured under
the same conditions. For all the experiments cells were recov-
ered by trypsinisation (TrypLE™ Express) for 5 min at 37 °C.
Microarray screening
A suspension of hES-MPs (4 mL) was added to the microarray
slides (initial screen n = 2, the ‘focused arrays’ n = 3) at 1.2 ×
104 cells cm−2, placed in a 4-well rectangular chamber. After
incubation, the slides were washed with PBS and the cells
fixed with 4% formaldehyde in PBS for 10 min, stained with
DAPI (0.1 µg mL−1 in PBS) for 10 min, and washed 3 times
with PBS. In the initial screen, polymers with ≥5 cells per
Fig. 1 An outline of the polymer microarray approach to identify and verify lead polymers for long term MSC culture. (A) In an initial screen hES-MPs
were incubated for 24 h on polymer microarrays and the polymers evaluated for cell binding. (B) A focused screen with microarrays containing
171 polymers from the initial screen. Each polymer feature was evaluated for cell number (DAPI), viability, and STRO-1 and CD105 marker intensity.
The top 30 polymers were coated on cover slips (ϕ 10 mm) and after 7 days of culture, cells were stained with DAPI and CellTracker Green, and for
STRO-1, CD105 and CD271. (C) 3 ‘lead’ polymers were validated in long-term cultures with hES-MPs (5 passages) and ADMSCs (10 passages) on
polymer coated coverslips. Extensive MSC marker analysis (CD73, CD90, CD105, STRO-1, HLA-DR, CD146, CD271, CD140b, CD34, CD14) was carried
out using ﬂow cytometry. ADMSCs were diﬀerentiated down the adipogenic and osteogenic lineages at passage 5.
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feature were selected. The ‘focused arrays’ were assessed for
cell count (DAPI), cell viability (CellTracker Green) and
immunostained for STRO-1 and CD105.
Immunocytochemistry
Cells on the arrays were stained using standard immunocyto-
chemistry protocols. For the ‘focused arrays’, polymer coated
coverslips and the gelatin and tissue culture plastic controls,
the cells were blocked for 1 h with 10% FCS in PBS. They were
then incubated overnight at 4 °C with primary antibodies
against STRO-1 (mouse anti-human, Millipore), CD105 (goat
anti-human, R&D systems) both at 1 : 100 dilution, and for the
scale-up experiment also with CD271 (rabbit anti-human,
Millipore) at 1 : 50 dilution. The cells were incubated for 4 h
with the appropriate AlexaFluor®-conjugated secondary anti-
bodies; STRO-1 (donkey anti-mouse 488) at 1 : 200, CD105
(donkey anti-goat 555) at 1 : 400 and CD271 (chicken anti-
rabbit) at 1 : 100 dilution. Excess antibody was removed by
washing 3 times with PBS. Finally, cells were stained with
DAPI (0.1 µg mL−1 in PBS) and washed 3 times with PBS.
Coating of polymers on coverslips
Glass coverslips (Menzel-Gläser, Germany), 10 mm (scale-up
experiments) and 32 mm diameter (long term culture), were
washed with tetrahydrofuran (THF) and spin-coated with 1%
(w/v) polymer solutions in THF or NMP for 2 s at 2000 rpm.
The coverslips were dried overnight in a vacuum oven
(200 mbar) at 40 °C. The coated coverslips were sterilised with
UV light for 20 min prior to cell culture.
Scale-up culture and analysis on 30 polymers
48-Well plates were coated with 0.5% agarose solution (100 µL
per well) and dried overnight at 50 °C. Polymer coated cover-
slips (n = 4) were placed into the wells and sterilised by UV
irradiation for 20 min and washed twice with PBS, the tissue
culture plastic controls consisted of 48-well plates, the gelatin
controls were 48-well plates coated with a 500 µL 0.1% gelatin
solution (in PBS). This was followed by seeding with hES-MPs
at 1 × 104 cells per well. Media was changed every 2 days. At
day 7, cells were washed with PBS, fixed with 4% form-
aldehyde, stained with DAPI (1 µg mL−1 in PBS) and triple
immunostained for STRO-1, CD105 and CD271. Each well was
imaged 9 times on four channels: 360 nm (DAPI), 488 nm
(STRO-1), 555 nm (CD105) and 649 nm (CD271). Stained
nuclei were counted and the fluorescence intensity measured
for each image to give cells mm−2 and intensity mm−2 (the
intensity was normalised to the cell number). The background
fluorescence for each polymer was calculated using a replicate
stained only with the secondary antibody and deducted from
sample fluorescence to give a corrected fluorescence intensity
value for each polymer.
Long-term passaging
hES-MPs and ADMSCs were seeded at 3 × 104 cells per well
onto 32 mm diameter polymer coated coverslips (n = 3), which
were placed into agarose coated 6-well plates (0.5% agarose,
500 µL per well). For gelatin controls, 6-well tissue culture
plates were treated with 0.1% gelatin in PBS (3 mL per well)
for 5 min, and the excess solution removed prior to the appli-
cation of cells and media. Media was changed every 2–3 days
and cells were passaged every 5–6 days at a 1 : 6 splitting ratio.
At passage 5 (hES-MPs and ADMSCs) and passage 10
(ADMSCs) cells where stained for CD105, STRO-1, CD271,
CD90, CD73, CD34, CD14, CD146, CD140b, and HLA-DR, and
analysed by flow cytometry.
Flow cytometry
For flow cytometry analysis, cells from each replicate (n = 3)
were trypsinised. After removing media and washing with PBS,
TrypLE™ Express (500 µL) was added to each well for 5 min
and subsequently neutralised with media (2 mL). The cells
were spun down (5 min, 1000 rpm) and resuspended in 600 µL
of FACS-PBS (PBS with 0.1% of BSA and NaN3). To 100 µL of
cell suspension 2 µL of the designated fluorescent-conjugated
antibody was added; CD105–FITC (Biolegend), STRO-1–APC
(Biolegend), CD73–PE (BD Bioscience), HLA-DR–FITC (BD bio-
science), CD14–PE (BD Biosciences), CD34–PE (Biolegend)
CD140b–APC (BD Biosciences), CD271–PE (BD Bioscience),
CD146–FITC (eBiosciences) and CD90–FITC (Biolegend). After
incubation for 20 min at 4 °C, 2 mL of FACS-PBS was added to
each tube and the tubes centrifuged for 7 min (475 rpm). The
PBS was gently decanted ensuring the pellet was not dislodged
and the cells resuspended in 250 µL of FACS-PBS and analysed
on a FACSCalibur flow cytometer. Flow cytometry histograms
were generated using FlowJo.
Osteogenic and adipogenic diﬀerentiation
After 5 passages on PU157, PU108, PA338, tissue culture
plastic and gelatin, ADMSCs were plated at 1.9 × 104 cells per
well (n = 3) in standard tissue culture 12-well plates for osteo-
genic diﬀerentiation, and 3.8 × 104 cells per well (n = 3) for
adipogenic diﬀerentiation. After 24 h the media was changed
to StemPro osteogenic or adipogenic diﬀerentiation media and
the cells were cultured for 28 days with media changes every
3–4 days. After washing with PBS, the cells were fixed in 4%
formaldehyde and stained with DAPI (1 μg mL−1). Osteo-
induced cells were stained with 2% Alizarin red S solution (pH
4.2) and adipo-induced cells with Oil Red O solution (3 parts
of 0.5% Oil Red O in isopropanol to 2 parts of water). Adipo-
cyte diﬀerentiation was quantified by comparing the number
of DAPI stained nuclei with the number of diﬀerentiated cells.
Osteogenic diﬀerentiation was evaluated by amount of Alizarin
red S positive pixels in osteogenic diﬀerentiation images with
imageJ by setting the image/adjust/colour threshold option.
The analyse option (analyse particles) calculated the percen-
tage of pixels above threshold. The best and poorest Alizarin
red S stained wells were used as reference points.26,27
Image capture
Image capture and analyses from the polymer microarrays and
the coated cover slips (on 48-well plates), tissue culture plastic
and gelatin wells, was carried out using a Nikon Eclipse 50i
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microscope with the Pathfinder software (IMSTAR, France).
The diﬀerentiated cells and the stem cells in the long term cul-
tures on coated cover slips were imaged with a Zeiss Observer
microscope.
Results and discussion
Screening on polymer microarrays
Two polymer libraries, a ‘PA-library’ (consisting of 453 copoly-
mers synthesised from acrylate, acrylamide and vinyl mono-
mers) and a ‘PU-library’ (204 polyurethanes), were investigated
using polymer microarray technology. The libraries were con-
structed to contain a diverse range of monomers (ESI
Fig. S1–S3†) with the aim to produce cell compatible surfaces
with a range of physico-chemical properties, such as variation
in overall charge, lipophilicity and wettability.
The two libraries were printed onto agarose coated glass
slides with each polymer printed in quadruplicate (Fig. 1A).28
In the initial screen hES-MPs were incubated for 24 h on the
microarrays to enable the identification of polymers that facili-
tated cell binding, as assessed by counting DAPI stained
nuclei on each polymer feature. From this initial screen, 171
polymer candidates were identified (ESI Fig. S4†).
Based on cell binding from the initial screen, a new
‘focused array’ (171 polymers, n = 6) was fabricated (Fig. 1B).
The new arrays were incubated with hES-MPs for 2, 4 or 7 days,
and analysed for cell binding on each polymer. In order to
compensate for any variation in feature size between diﬀerent
polymers, the features were measured and the cell counts
given as cells mm−2. Certain polymers showed an increase in
cell numbers with increasing culture time indicating that the
substrates facilitated both binding and growth (ESI Fig. S5†).
In addition, cell viability was assessed at day 7 (ESI Fig S6†).
The phenotype of the hES-MPs was assessed at each time
point by staining the arrays for two well-known MSC markers,
STRO-1 and CD105 (Fig. 1B, ESI Fig. S7 and S8†).29–32 Staining
of hES-MPs with DAPI, CellTracker Green, STRO-1 and CD105
on the ‘focused array’ after 7 days incubation identified several
polymers that could maintain growth, showed good cell viabi-
lity, and conserved/enhanced the expression of the two
markers. To select substrates that would favour the multi-
potent stem cells over less potent progenitors, criteria for
selecting candidates for larger scale studies took into consider-
ation marker intensities as well as cell count and viability. The
best polymers in terms of number of cells mm−2, cell viability,
STRO-1 intensity and CD105 intensity were ranked, with the
30 highest ranking polymers selected for more detailed studies
(ESI, Table S1†).
Lead identification
The top 30 polymer candidates were coated onto glass cover-
slips and incubated with hES-MPs for 7 days using gelatin
and tissue culture plastic as controls, followed by staining
with DAPI, CD105, STRO-1, and an additional marker CD271.
CD271 is considered to be a good marker for multipotent
characterisation33 and was included to provide additional cri-
teria for lead polymer selection. Overexpression of CD271 inhi-
bits the diﬀerentiation of MSCs into osteogenic, chondrogenic,
and myogenic lineages, clearly an important role in maintain-
ing the MSC state.34
After 7 days of culture, 5 polymers showed better or similar
levels of cell growth compared to gelatin or tissue culture
plastic (Fig. 2A). The two top polymers, PA338 and PU108,
closely resembled gelatin in terms of marker expression and
were chosen as ‘lead’ substrates (Fig. 2 and 3). On larger sur-
faces, PU157 showed relatively modest cell growth but con-
siderably enhanced STRO-1, CD105, and CD271 intensities
Fig. 2 (A) The number of hES-MPs mm−2 for each of the 30 polymer candidates after 7 days incubation on polymer coated coverslips (n = 3). The
blue bars represent polymers selected as ‘leads’. (B) Relative marker intensity for STRO-1, CD105 and CD271 for hES-MPs grown on the 3 ‘lead’ poly-
mers PU157, PU108 and PA338, and for gelatin (GEL) and tissue culture plastic (TCP) (n = 3). (C) Examples of images of cells grown on the ‘lead’
polymer PU157 stained with DAPI and for the markers STRO-1, CD105 and CD271.
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(Fig. 2B), and was therefore taken forward as the third ‘lead’
polymer for long-term culture and characterisation with
hES-MPs and ADMCSs.
Long-term culture and characterisation of hES-MPs
For extended culture on the lead polymers PU157, PU108 and
PA338 (Fig. 3), a variety of MSC markers were used to fully
probe the suitability of the substrates for long-term MSC
culture. In addition to CD105, STRO-1 and CD271, seven
additional markers were used. These included positive
markers CD90 and CD73, and negative markers CD14 and
CD34, chosen because they are used as part of the minimal cri-
teria for defining MSCs.29 However, CD34 positive populations
are present in MSCs obtained from adipose tissue35 and MSC
marker expression in general has been shown to depend on
the source.36 CD146 and CD140b were selected as these are
considered to be in vivo MSC markers,5 whereas HLA-DR is a
standard negative marker for MSCs as well as an indicator of
the immune modulatory state of MSCs (HLA-DR is up regulated
when MSCs are primed into their immune modulatory state).37
Prior to the long-term culture on the ‘lead’ polymers,
hES-MPs were characterised at ‘passage 0’, i.e., the point of
removal from gelatin, for the expression of CD105, STRO-1,
CD271, CD90, CD73, CD34, CD14, CD146, CD140b, and
HLA-DR (Fig. 4A). Here, cells were positive for CD73 and
STRO-1 (100% and 99%, respectively), positive for CD105 and
CD90 (91% and 83%, respectively), and moderately positive for
CD34, CD146 and CD14 (CD14 was subsequently down regu-
lated). hES-MPs grown on the ‘lead’ polymers were assessed
with these 10 markers at passage 5 to monitor marker conser-
vation or changes in the marker expression levels.
Flow cytometry analysis at passage 5 showed that hES-MPs
cultured on PU108, PU157 and PA338 expressed similar levels
of the markers to cells grown on gelatin (Fig. 4A, ESI Fig. S9†).
However CD105, which is considered one of the essential
markers for MSCs, expression was reduced on cells grown on
all ‘lead’ polymers, but levels were comparable with gelatin.
Interestingly, hES-MPs are currently derived through serial pas-
saging of hESCs on gelatin.38 Notably, CD105 was lost at
passage 5 on tissue culture plastic (Fig. 4A and 5).
The marker CD90, which is bimodal in hES-MPs,38,39
showed a substantial increase in the negative fraction with
culture on PA108 when compared to other substrates (Fig. 5).
However, hES-MPs cultured on PU157 and PA338 maintained
CD90 at levels similar to tissue culture plastic and gelatin
(73%, 74% 70% and 82% of positive cells for PU157, PA338,
tissue culture plastic and gelatin, respectively). Decreasing
levels of CD90 have been associated with the loss of the
immune modulatory properties of MSCs.40 The comparatively
low expression of this marker in hES-MPs in general, com-
pared to adult derived MSCs, may explain the fact why
hES-MPs do not possess the property of immune modulation
associated with adult derived MSCs.39 The ability of PU157
and PA338 to maintain marker expression (including CD105
and CD90) similar to gelatin indicates that they may act as
chemically defined alternatives to gelatin for serial passaging
of hESCs to produce hES-MPs.
Long-term culture and characterisation of ADMSCs
ADMSCs grown on PU157, PU108 and PA338, closely
resembled the gelatin control with most of the MSC markers at
passage 5 (Fig. 4B, ESI Fig. S10†). At passage 5, ADMSCs grown
on tissue culture plastic, gelatin, PU157, PU108 and PA338
were positive for CD105, although a loss in marker intensity
was observed with all substrates when compared to ‘passage 0’
(Fig. 6A).
A further reduction in the CD105 marker intensity was
observed by passage 10 with PU157, PU108 and PA338 (49%,
54% and 49% of positive cells, respectively), although with
cells grown on gelatin and tissue culture plastic the levels were
maintained (85% and 81%, respectively) (Fig. 4B, 6B and
ESI S11†).
Surprisingly, the ADMSCs clearly expressed HLA-DR at
‘passage 0’, however, on gelatin this marker was subsequently
down regulated by passage 5. The cells grown on tissue culture
plastic and PU108 continued to be positive for this marker up
to passage 10 (76% and 69%, respectively). However, PU157
and PA338 showed reduced expression of HLA-DR by passage 5
(35% and 38% positive, respectively), with low levels main-
tained by passage 10 (Fig. 4B, 6A and B). The expression of
HLA-DR at ‘passage 0’ may indicate an inflammatory environ-
ment from where the ADMSCs were sourced (IFN-γ upregulates
this receptor in MSCs). Prior to their application in therapy,
MSCs are treated with IFN-γ to prime them into the immune
modulatory state, corresponding to upregulation of the
HLA-DR receptor.41 Whether upregulation of the receptor
through substrate interaction is an indicator that the substrate
could prime the cells into the immune modulatory state is an
interesting question.
At the start (‘passage 0’), ADMSCs showed a 44% positive
population for STRO-1. By passage 5 there was a distinct posi-
tive shift in STRO-1 intensity with tissue culture plastic, which
Fig. 3 Structures of the copolymers PU157, PU108 and PA338. PU157
was synthesised from poly(butyleneglycol) (mw 250) and 4,4’-methy-
lenediphenyldiisocyanate with 3-(dimethylamino)-1,2-propanediol as an
extender, PU108 from poly(butyleneglycol) (mw 1000) and hexamethy-
lenediisocyanate with 3-(diethylamino)-1,2-propanediol as an extender.
PA338 is N-methylaniline modiﬁed poly(methylmethacrylate-co-glyci-
dylmethacrylate) (synthesised in 1 : 1 monomer ratio).
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became even more pronounced by passage 10 (Fig. 6A
and B).42 High expression of STRO-1 has been associated with
an increase in adipogenic and osteogenic markers PPAR-G and
RUNX2, respectively, and upregulation of either of these
markers could reduce the ability of the cells to diﬀerentiate
down the other lineage.43
Diﬀerentiation of ADMSCs
At passage 5, ADMSCs grown on PU157, PU108, PA338, gelatin,
and tissue culture plastic were diﬀerentiated down the adi-
pogenic and osteogenic lineages to evaluate if they retained
their diﬀerentiation potential. Histological staining of the cells
Fig. 4 Flow cytometry analysis of 10 MSC markers for hES-MPs (A) and ADMSCs (B) prior to the culture on PU157, PU108 and PA338, termed
‘passage 0’ (p0), and at passage 5 (p5) and 10 (p10) (ADMSCs only) on PU157, PU108, PA338, gelatin (GEL), and tissue culture plastic (TCP).
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Fig. 5 Representative ﬂow cytometry traces of the markers CD105 and CD90 with hES-MPs at ‘p0’ and p5 on gelatin (GEL), tissue culture plastic
(TCP), PU157, PU108 and PA338 (red trace for stained cells, black for unstained cells).
Fig. 6 Representative ﬂow cytometry traces of the markers CD105, HLA-DR and STRO-1 with ADMSCs at ‘p0’, p5 (A) and p10 (B) on gelatin (GEL),
tissue culture plastic (TCP), PU157, PU108 and PA338 (red trace for stained cells, black for unstained cells).
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with Alizarin Red and Oil red O showed that the cells had
diﬀerentiated down the osteogenic and adipogenic lineages,
respectively, proving that the cells had clearly maintained their
multi-lineage potential (Fig. 7A). Also, the ADMSCs grown on
various substrates showed no major diﬀerence in the pro-
portion of cells capable of diﬀerentiating down the adipogenic
lineage (Fig. 7B). Image analysis of the Alizarin Red S stained
cells showed that PA338, gelatin and tissue culture plastic had
comparable levels of staining, whereas PU157 and PU108
showed somewhat lower levels of staining (ESI Fig. S12†).26 A
similar ability of ADMSCs to diﬀerentiate at passage 5, regard-
less of which substrate they were grown on, suggests that the
diﬀerences seen in marker expression at this passage has no
significant eﬀect on their diﬀerentiation capacity.
Polymer analysis
To investigate if the chemical composition of the polymer
surface can be correlated to cell binding/growth and stem cell
maintenance, the monomers present in the top candidates
from the scale up studies were analysed. The top ten perform-
ing polymers from the PA-library showed some monomers to
be highly preferred over others (ESI Fig. S13 and S14†). Methyl
methacrylate was present in 8 out of the 10 top polymers, and
9 polymers contained a monomer with a tertiary amine, with
aliphatic amines (6 out of 9) rendering the surface positively
charged at physiological pH. In addition, the presence of an
aryl ring seemed beneficial (PA338 is a copolymer of methyl
methacrylate and N-methylaniline functionalised glycidyl
methacrylate.
Analysis of the top 10 polyurethanes from the scale-up
experiments showed 4,4′-methylenebis(phenylisocyanate) and
poly(butyleneglycol) were present in 8 and 5 polymers, respect-
ively, both of which were present in the lead PU157 along
with 3-dimethylamino-1,2-propanediol (ESI Fig. S15 and S16†).
Certain monomers, e.g. poly(ethylene glycol) (PEG), seemed
disadvantageous in terms of binding and promotion of
growth.
Adhesion of a cell on the surface is a complex process
depending on a combination of cell–protein and polymer–
protein interactions, and the physico-chemical properties of
the surface. In stem cell culture, the ability of the substrate to
maintain the cells in their stem cell state adds another level of
complexity to the material–cell interactions. Therefore,
although some common features could be found on the com-
position of non-binding versus binding polymers, drawing
direct ‘structure–function relationships’ for polymer surfaces
and stem cell maintenance remains a challenge, further high-
lighting the advantages of a high-throughput approach for the
discovery of new substrates.
Surface characterisation
Of the lead polymers, PA338 and PU157 had a water contact
angle of 81° and 70°, respectively (representative control poly-
mers, which showed no or poor cell binding or growth, had
contact angles of 27–67°) (ESI Table S2†). However, PU108 had
a relatively small water contact angle of 46°, suggesting that
water contact angle or the surface energy is a poor indicator
of stem cell adhesion/growth in the polymer libraries
investigated.
To investigate global protein binding on the polymer sur-
faces, polymer coated cover slips were treated with culture
media (supplemented with 10% FCS) for 24 h, and adhered
proteins analysed by gel electrophoresis (ESI Fig. S17†). With
the exception of PU108, which showed slightly diﬀerent
protein binding pattern, all the studied polymers, including
poor cell binder controls, showed protein binding similar to
gelatin and tissue culture plastic, thus suggesting that the
surface chemistry plays an important role in the cell adhesion
and growth, although subtle changes in binding of low abun-
dance proteins cannot be ruled out.
Conclusions
By using hES-MPs in a ‘three-step’ screening strategy, which
consisted of two iterative rounds of polymer microarray
screens followed by a large scale 30 polymer study, a number
of polymers were identified that could potentially support
long-term MSC culture. Based on cell growth and the intensity
of markers CD105, STRO-1 and CD271, two polyurethanes
(PU157 and PU108) and one polyacrylate (PA338), were identi-
fied as ‘lead’ substrates. hES-MPs and ADMSCs were cultured
on PU157, PU108 and PA338 for 5 and 10 passages, respect-
Fig. 7 (A) Histological staining of ADMSCs diﬀerentiated down the
osteogenic lineage with red staining indicating calcium deposits (Ala-
zarin Red S) and ADMSCs diﬀerentiated down the adipogenic lineage
with red spots indicating fat droplets (Oil red O). (B) The percentage of
ADMSCs (n = 3) that diﬀerentiated down the adipogenic lineage after 5
passages on gelatin (GEL), tissue culture plastic (TCP), PU157, PU108
and PA338.
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ively, and analysed for 10 MSC markers. All substrates showed
similar growth rates for both cell types. After 5 passages on the
polymer substrates, both cell types expressed similar marker
levels as control cells grown on gelatin, whereas on tissue
culture plastic the marker CD105 was lost (hES-MPs). hES-MPs
cultured on PU108 showed an increase in the negative fraction
for CD90 and ADMSCs cultured on PU108 continued to
express HLA-DR at passage 10. Irrespective of some variation
in the marker expression between ADMSCs grown on diﬀerent
substrates, the cells were successfully diﬀerentiated into osteo-
blasts and adipocytes at passage 5. Overall, PU157 and PA338
showed the most similarity to gelatin and eﬃciently main-
tained growth and conserved phenotype over multiple pas-
sages for both hES-MPs and ADMSCs. As a potential
alternative to gelatin, PU157 and PA338 oﬀer chemically
defined synthetic polymer substrates for eﬃcient long term
MSC culture.
Acknowledgements
This work was supported by EU FP7 funding (project 223410,
BEST Stem Cells). We thank Kay Samuel for help with the flow
cytometry experiments, Drs Anne Hansen and Mei Wu for
assistance with the microarray fabrication, Dr Steve Pells for
input on figure preparation, and Drs Chris Armit and Marieke
Hoeve for helpful discussions.
Notes and references
1 A. J. Friedenstein, U. F. Deriglasova, N. N. Kulagina,
A. F. Panasuk, S. F. Rudakowa, E. A. Luriá and
I. A. Ruadkowet, Precursors for fibroblasts in diﬀerent
populations of hematopoietic cells as detected by the in
vitro colony assay method, Exp. Hematol., 1974, 2, 83–92.
2 M. W. Lee, J. Choi, M. S. Yang, Y. J. Moon, J. S. Park,
H. C. Kim and J. K. Young, Mesenchymal stem cells from
cryopreserved human umbilical cord blood, Biochem.
Biophys. Res. Commun., 2004, 16, 273–278.
3 H. Wang, S. Hung, S. Peng, C. Huang, H. Wei, Y. Guo,
F. Yu-Show, C. Mei-Lai and C. Chin-Chang, Mesenchymal
stem cells in the Wharton’s jelly of the human umbilical
cord, Stem Cells, 2004, 22, 1330–1337.
4 P. A. Zuk, M. Zhu, H. Mizuno, J. I. Huang, W. J. Futrell,
A. J. Katz, P. Benhaim, H. P. Lorenz and M. H. Hedrick,
Multilineage cells from human adipose tissue: implications
for cell-based therapies, Tissue Eng., 2001, 7, 211–226.
5 M. Crisan, S. Yap, L. Casteilla, C. W. Chen, M. Corselli,
T. S. Park, G. Andriolo, B. Sun, B. Zheng, L. Zhang,
C. Norotte, P. N. Teng, J. Traas, R. Schugar, B. M. Deasy,
S. Badylak, H. J. Buhring, J. P. Giacobino, L. Lazzari,
J. Huard and B. Péault, A perivascular origin for mesenchy-
mal stem cells in multiple human organs, Cell Stem Cell,
2008, 3, 301–313.
6 M. F. Pittenger, A. M. Mackay, S. C. Beck, R. K. Jaiswal,
R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti,
S. Craig and D. R. Marshak, Multilineage potential of adult
human mesenchymal stem cells, Science, 1999, 284, 143–147.
7 S. Wakitani, T. Saito and A. I. Caplan, Myogenic cells
derived from rat bone marrow mesenchymal stem cells
exposed to 5-azacytidine, Muscle Nerve, 1995, 18, 1417–
1426.
8 P. Tropel, N. Platet, J. C. Platel, D. Noël, M. Albrieux,
A. L. Benabid and F. Berger, Functional neuronal diﬀeren-
tiation of bone marrow-derived mesenchymal stem cells,
Stem Cells, 2006, 24, 2868–2876.
9 L. Wang, L. Ott, K. Seshareddy, M. L. Weiss and
M. S. Detamore, Musculoskeletal tissue engineering with
human umbilical cord mesenchymal stromal cells, Regen.
Med., 2011, 6, 95–109.
10 H. M. Lazarus, O. N. Koc, S. M. Devine, P. Curtin,
R. T. Maziarz, H. K. Holland, E. J. Shpall, P. McCarthy,
K. Atkinson, B. W. Cooper, S. L. Gerson, M. J. Laughlin,
F. R. Loberiza Jr., A. B. Moseley and A. Bacigalupo, Cotrans-
plantation of HLA-identical sibling culture-expanded
mesenchymal stem cells and hematopoietic stem cells in
hematologic malignancy patients, Biol. Blood Marrow Trans-
plant., 2005, 11, 389–398.
11 P. Fiorina, M. Jurewicz, A. Augello, A. Vergani, S. Dada,
S. La Rosa, M. Selig, J. Godwin, K. Law, C. Placidi,
R. N. Smith, C. Capella, S. Rodig, C. N. Adra, M. Atkinson,
M. H. Sayegh and R. Abdi, Immunomodulatory function of
bone marrow-derived mesenchymal stem cells in experi-
mental autoimmune type 1 diabetes, J. Immunol., 2009,
183, 993–1004.
12 J. Cohen, Mesenchymal stem cell transplantation in mul-
tiple sclerosis, J. Neurol. Sci., 2013, 333, 43–49.
13 A. Augello, R. Tasso, S. M. Negrini, R. Cancedda and
G. Pennesi, Cell therapy using allogeneic bone marrow
mesenchymal stem cells prevents tissue damage in col-
lagen-induced arthritis, Arthritis Rheum., 2007, 56, 1175–
1186.
14 J. R. Mauney, D. L. Kaplan and V. Volloch, Matrix-mediated
retention of osteogenic diﬀerentiation potential by human
adult bone marrow-derived mesenchymal stem cells during
ex vivo expansion, Biomaterials, 2004, 25, 3233–3243.
15 J. R. Mauney, V. Volloch and D. L. Kaplan, Matrix-mediated
retention of adipogenic diﬀerentiation potential by human
adult bone marrow-derived mesenchymal stem cells during
ex vivo expansion, Biomaterials, 2005, 26, 6167–6175.
16 M. Pevsner-Fischer, S. Levin and D. Zipori, The origins of
mesenchymal stromal cell heterogeneity, Stem Cell Rev.,
2011, 7, 560–568.
17 H. Mizomoto, The synthesis and screening of polymer
libraries using a high throughput approach, PhD Thesis, Uni-
versity of Southampton, 2004.
18 D. G. Anderson, D. Putnam, E. B. Lavik, T. A. Mahmood
and R. Langer, Biomaterial microarrays: rapid, microscale
screening of polymer-cell interaction, Biomaterials, 2005,
26, 4892–4897.
Biomaterials Science Paper
This journal is © The Royal Society of Chemistry 2014 Biomater. Sci., 2014, 2, 1683–1692 | 1691
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
0 
Ju
ly
 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
7/
11
/2
01
4 
11
:5
2:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
19 M. Wu, H. Bridle and M. Bradley, Targeting Cryptospori-
dium parvum capture, Water Res., 2012, 46, 1715–1722.
20 S. Pernagallo, M. Wu, M. P. Gallagher and M. Bradley, Colo-
nising new frontiers-microarrays reveal biofilm modulating
polymers, J. Mater. Chem., 2011, 21, 96–101.
21 A. Hansen, L. McMillan, A. Morrison, J. Petrik and
M. Bradley, Polymers for the rapid and eﬀective activation
and aggregation of platelets, Biomaterials, 2011, 32, 7034–
7041.
22 D. G. Anderson, S. Levenberg and R. Langer, Nanoliter-
scale synthesis of arrayed biomaterials and application to
human embryonic stem cells, Nat. Biotechnol., 2004, 22,
863–866.
23 A. Hansen, H. K. Mjoseng, R. Zhang, M. Kalloudis,
V. Koutsos, P. A. de Sousa and M. Bradley, High-Density
Polymer Microarrays: Identifying Synthetic Polymers that
Control Human Embryonic Stem Cell Growth, Adv. Health-
care Mater., 2013, 3, 848–853.
24 C. R. E. Duﬀy, R. Zhang, S.-E. How, A. Lilienkampf, P. A. de
Sousa and M. Bradley, Long term mesenchymal stem cell
culture on a defined synthetic substrate with enzyme free
passaging, Biomaterials, 2014, 35, 5998–6005.
25 R. Zhang, H. Mjoseng, M. Hoeve, N. Bauer, S. Pells,
R. Besseling, S. Velugotla, G. Tourniaire, R. Kishen,
Y. Tsenkina, C. Armit, C. R. E. Duﬀy, M. Helfen,
F. Edenhofer, P. A. de Sousa and M. Bradley, A thermo-
responsive and chemically defined hydrogel for long-term
culture of human embryonic stem cells, Nat. Commun.,
2013, 4, 1335–1342.
26 A. Mehlem, C. E. Hagberg, L. Muhl, U. Eriksson and
A. Falkevall, Imaging of neutral lipids by oil red O for ana-
lyzing the metabolic status in health and disease, Nat. Pro-
tocols, 2013, 8, 1149–1154.
27 M. T. Yang, J. Fu, Y.-K. Wang, R. A. Desai and C. S. Chen,
Assaying stem cell mechanobiology on microfabricated
elastomeric substrates with geometrically modulated rigid-
ity, Nat. Protocols, 2011, 6, 187–213.
28 S. Pernagallo, J. J. Diaz-Mochon and M. Bradley, A coopera-
tive polymer-DNA microarray approach to biomaterial
investigation, Lab Chip, 2009, 3, 397–403.
29 M. Dominici, K. Le Blanc, I. Mueller, I. Slaper-Cortenbach,
F. Marini, D. Krause, R. Deans, A. Keating, D. Prockop and
E. Horwitz, Minimal criteria for defining multipotent
mesenchymal stromal cells. The International Society for
Cellular Therapy position statement, Cytotherapy, 2006, 8,
315–317.
30 J. E. Dennis, J. P. Carbillet, A. I. Caplan and P. Charbord,
The STRO-1+ marrow cell population is multipotential,
Cells Tissues Organs, 2002, 170, 73–82.
31 P. J. Simmons and B. Torok-Storb, Identification of stromal
cell precursors in human bone marrow by a novel mono-
clonal antibody, STRO-1, Blood, 1991, 78, 55–62.
32 S. Gronthos, D. M. Franklin, H. A. Leddy, R. Storms and
J. M. Gimble, Characterization of surface protein
expression on human adipose tissue-derived stromal cells,
J. Cell Physiol., 2001, 189, 54–63.
33 H. J. Buhring, V. L. Battula, S. Treml, B. Schewe, L. Kanz
and W. Vogel, Novel markers for the prospective
isolation of human MSCs, Ann. N. Y. Acad. Sci., 2007, 1106,
262–271.
34 Y. Mikami, Y. Ishii, N. Watanabe, T. Shirakawa, S. Suzuki,
S. Irie, K. Isokawa and M. J. Honda, CD271/P75ntr Inhibits
the diﬀerentiation of mesenchymal stem cells into osteo-
genic, adipogenic, chondrogenic and myogenic lineages,
Stem Cells Dev., 2011, 20, 901–913.
35 M. Corselli, C. W. Chen, B. Sun, S. Yap, J. P. Rubin and
B. Péault, The tunica adventitia of human arteries and
veins as a source of mesenchymal stem cells, Stem Cells
Dev., 2012, 21, 1299–1308.
36 A. A. Nery, I. C. Nascimento, T. Glaser, V. Bassaneze,
J. E. Krieger and H. Ulrich, Human mesenchymal stem
cells: from immunophenotyping by flow cytometry to clini-
cal applications, Cytometry A, 2013, 83, 48–61.
37 N. Singer and A. Caplan, Mesenchymal Stem Cells: Mecha-
nisms of Inflammation, Annu. Rev. Pathol.: Mech. Dis.,
2011, 6, 457–478.
38 C. Karlsson, K. Emanuelsson, F. Wesserg, K. Kajic,
M. Z. M. Axell, P. S. Eriksson, A. Lindahl, J. Hyllner and
R. Strehl, Human embryonic stem cell-derived mesenchy-
mal progenitors-potential in regenerative medicine, Stem
Cell Res., 2009, 3, 39–50.
39 O. Li, A. Tormin, B. Sundberg, J. Hyllner, K. Le Blanc and
S. Scheding, Human embryonic stem cell-derived
mesenchymal stroma cells (hES-MSCs) engraft in vivo and
support hematopoiesis without suppressing immune func-
tion: implications for oﬀ-the shelf ES-MSC therapies, PLoS
One, 2013, 8, e55319.
40 D. Campioni, R. Rizzo, M. Stignani, L. Melchiorri,
L. Ferrari, S. Moretti, A. Russo, G. P. Bagnara, L. Bonsi,
F. Alviano, G. Lanzoni, A. Cuneo, O. R. Baricordi and
F. Lanza, A decreased positivity for CD90 on human
mesenchymal stromal cells (MSCs) is associated with a loss
of immunosuppressive activity by MSCs, Cytometry, Part B,
2009, 76, 225–230.
41 W. K. Chan, A. S. Lau, J. C. Li, H. K. Law, Y. L. Lau and
G. C. Chan, MHC expression kinetics and immunogenicity
of mesenchymal stromal cells after short-term IFN-γ chal-
lenge, Exp. Hematol., 2008, 36, 1545–1555.
42 R. H. Lee, M. J. Seo, A. A. Pulin, C. A. Gregory, J. Ylostalo
and D. J. Prockop, The CD34-like protein PODXL and
α6-integrin (CD49f) identify early progenitor MSCs with
increased clonogenicity and migration to infarcted heart in
mice, Blood, 2009, 113, 816–826.
43 S. Isenmann, A. Arthur, C. W. A. Zennettino, J. L. Turner,
S. Shi, C. A. Glackin and S. Grunthos, TWIST family of
basic helix-loop-helix transcription factors mediate human
mesenchymal stem cell growth and commitment, Stem
Cells, 2009, 27, 2457–2468.
Paper Biomaterials Science
1692 | Biomater. Sci., 2014, 2, 1683–1692 This journal is © The Royal Society of Chemistry 2014
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
0 
Ju
ly
 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
7/
11
/2
01
4 
11
:5
2:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
